They have more than an inkling. The last ADA conf. had multiple presentations proving that IL-1 blockade is very effective in T1D. One was given by Marc Donath. Xoma's lead investigator. So far Xoma is careful not to recognize the existance of the trial. Much like Xoma985 and the Cardiovascular disease trial.
It looks like something would have leaked though. Are the participants sworn to silence or something? I mean as closely as diabetics monitor their condition they'd surely note that there was a sea change and word would get out. I keep thinking about that 75,000 share block at the opening last week up $0.21.